VNDAHealthcare · BiotechnologyThe 5 Wall Street analysts covering Vanda Pharmaceuticals, Inc. hold a median 12-month price target of $11 — +175.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 28 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Vanda Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on VNDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +175.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Oct 2026 | HC Wainwright & Co. | Reiterates | Buy | $20 |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | — |
| 23 Sept 2026 | Oppenheimer | Initiates | Outperform | $10 |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | — |
| 10 Aug 2026 | B. Riley Securities | Reiterates | Buy | $17 → $12 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $21 → $20 |
| 10 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $21 |
| 11 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 23 Feb 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Dec 2025 | B. Riley Securities | Maintains | Buy | — |
| 31 Dec 2025 | Jefferies | Maintains | Hold | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2025 | B. Riley Securities | Initiates | Buy | — |
| 30 Oct 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2025 | Cantor Fitzgerald | Assumes | Overweight | $13 |
| 7 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VNDA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Vanda Pharmaceuticals, Inc. returned −28.3% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 6% of US stocks
Cheaper than 66% of US stocks
Cheaper than 67% of US stocks
Cheaper than 66% of US stocks
Higher than 21% of US stocks
Higher than 32% of US stocks
Higher than 97% of US stocks
Higher than 13% of US stocks
Higher than 5% of US stocks
Higher than 16% of US stocks
Higher than 18% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Vanda Pharmaceuticals, Inc. has a market value of $241.2M and an enterprise value of $94.0M.
Revenue in the twelve months to 30 June 2026: $215.7M. The latest quarter shrank 3.9% year on year.
Net income over the same four quarters: −$274.9M, a −127.4% net margin.
Diluted earnings per share, trailing twelve months: $−4.63.
Free cash flow in the twelve months to 30 June 2026: −$153.0M.
Trailing P/E: 126.0×; forward P/E: 19.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Vanda Pharmaceuticals, Inc. employs 533 people — $405K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Vanda Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Vanda Pharmaceuticals Inc.’s Q3 2026 earnings call.
Why it matters — The transcript provides VNDA watchers with a record of the company’s quarterly earnings-call discussion.
Vanda Pharmaceuticals reported third-quarter revenue growth of 24% year over year, supported by higher Fanapt sales and a sequential increase in HETLIOZ revenue partly tied to specialty-pharmacy purchasing and shipment timing. Operating expenses fell 18% from the second quarter as certain late-stage development and launch-preparation activities concluded.
Why it matters — The results highlight revenue growth alongside lower quarterly operating expenses, while noting that HETLIOZ’s sequential increase was partly affected by purchasing and shipment timing.
Vanda Pharmaceuticals reported a third-quarter loss of $0.37 per share, compared with the Zacks consensus estimate of a $0.72 loss. It reported a loss of $0.38 per share in the year-ago quarter.
Why it matters — The report gives VNDA watchers a quarterly earnings result that was a smaller loss per share than the cited consensus estimate and the year-ago result.
Vanda Pharmaceuticals reported Q3 2026 revenue of $69.8 million, up 24% year over year and 38% from Q2, while operating expenses fell 18% from Q2 to $93.3 million. The company also reported positive Phase III NEREUS results for prevention of GLP-1-induced vomiting and provided updates on NEREUS availability, BYSANTI launch timing, and Quimilza’s FDA review.
Why it matters — The results and product-program updates provide VNDA watchers with information on quarterly financial performance and the progress of its commercial and development programs.
Vanda Pharmaceuticals reported results from a Phase 3 trial evaluating Nereus, an oral therapy intended to prevent vomiting associated with GLP-1 receptor agonist treatments. The headline describes the trial outcomes as positive.
Why it matters — VNDA watchers may note the reported Phase 3 results for the company’s candidate targeting vomiting associated with GLP-1 treatments.
The 5 Wall Street analysts covering Vanda Pharmaceuticals, Inc. have a median 12-month price target of $11, with estimates ranging from $4.5 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Vanda Pharmaceuticals, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vanda Pharmaceuticals, Inc. 64 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Vanda Pharmaceuticals, Inc. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +175.0% from the last close, and Ticker Nerd's factor model ranks Vanda Pharmaceuticals, Inc. 64 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Vanda Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VNDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.5 to $20 over the next 12 months.
Vanda Pharmaceuticals, Inc. returned -28.3% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs.
The most recent item we track (Seeking Alpha, 29 Oct 2026): "Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Vanda Pharmaceuticals Inc.’s Q3 2026 earnings call.
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. Its current portfolio centers on treatments for sleep-wake disorders, schizophrenia, and other central nervous system conditions, supported by a selective pipeline that includes additional clinical and preclinical programs. The company’s marketed products include HETLIOZ and Fanapt, while PONVORY adds a presence in immune-related therapeutics. Vanda also works on specialty medicines for rare diseases and other targeted indications, using genetics and genomics to guide drug discovery and clinical development. With a concentrated product mix and a research-driven model, Vanda Pharmaceuticals Inc. plays a specialized role in the biopharmaceutical market by addressing niche patient populations where treatment options may be limited.
CEO Dr. Mihael H. Polymeropoulos M.D. · 533 employees · United States · https://www.vandapharma.com
